After the market closed on Wednesday, Arcus Biosciences (NYSE: RCUS) presented interim results from Arc-7 -- one of the most closely watched phase 2 clinical trials of the year. According to the company, patients who received the company's anti-Tigit antibody, domvanalimab, showed encouraging clinical activity.
Shares of Arcus rose on Thursday in response to the company's positive view of the study. But the lack of details provided was bad news for Arcus, its collaboration partner Gilead Sciences (NASDAQ: GILD) , and some of the biopharmaceutical industry's biggest players.
Image source: Getty Images.
For further details see:
Why Arcus Biosciences' Big Reveal Wasn't Very Exciting